Dostarlimab monotherapy in mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer in the Korean expanded access program

被引：0
|
作者：
Park, Soo Jin [1 ]
Lee, Yoo Young [2 ]
Kim, Kidong [3 ]
Nam, Eun Ji [4 ]
Lim, Myong Cheol [5 ]
Kim, Min Kyu [6 ]
Kim, Ki Hyung [7 ]
Kwon, Yong-Soon [8 ]
机构：
[1] Seoul Natl Univ Hosp, Obstet & Gynecol, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Gynecol Canc Ctr, Dept Obstet & Gynecol,Sch Med, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Obstet & Gynecol, Seongnam Si, South Korea
[4] Yonsei Univ, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Div Gynecol Oncol,Coll Med, Seoul, South Korea
[5] Natl Canc Ctr, Ctr Gynecol Canc, Goyang, South Korea
[6] Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Obstet & Gynecol, Chang Won, South Korea
[7] Pusan Natl Univ Hosp, Obstet & Gynecol, Busan, South Korea
[8] Eulji Univ, Coll Med, Nowon Eulji Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期
关键词：
D O I：
10.1136/ijgc-2023-IGCS.230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP134
引用
收藏
页码：A131 / A132
页数：2
相关论文
共 50 条
  • [1] An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
    Bartoletti, Michele
    Giorda, Giorgio
    Viel, Alessandra
    Fornasarig, Mara
    Zdjelar, Adrian
    Segatto, Enrica
    Sorio, Roberto
    Corsetti, Serena
    Scalone, Simona
    Nicoloso, Milena Sabrina
    Pivetta, Tania
    Lucia, Emilio
    Clemente, Nicolo
    Palazzari, Elisa
    Canzonieri, Vincenzo
    Puglisi, Fabio
    CURRENT ONCOLOGY, 2022, 29 (08) : 5209 - 5212
  • [2] DOSTARLIMAB IN ADVANCED/RECURRENT MISMATCH REPAIR DEFICIENT/MICROSATELLITE INSTABILITY HIGH OR PROFICIENT/STABLE ENDOMETRIAL CANCER: THE GARNET STUDY
    Oaknin, A.
    Gilbert, L.
    Tinker, A. V.
    Brown, J.
    Mathews, C.
    Press, J.
    Sabatier, R.
    O'malley, D. M.
    Samouelian, V.
    Boni, V.
    Duska, L.
    Ghamande, S.
    Ghatage, P.
    Kristeleit, R.
    Leath, C.
    Veneris, J.
    Duan, T.
    Im, E.
    Pothuri, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A85 - A86
  • [3] Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Boklage, Susan
    Hanlon, Jennifer
    Im, Ellie
    Brown, Jubilee
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (10) : 1250 - 1257
  • [4] Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer
    Shukla, Siddhant
    Patel, Harsh
    Chen, Shuzhen
    Sun, Rainie
    Wei, Liuya
    Chen, Zhe-Sheng
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (03): : 135 - 141
  • [5] Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana
    Mangan, Niamh
    Miller, Rowan E.
    Pikiel, Joanna
    Mirza, Mansoor R.
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer
    Tinker, Anna V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 133 - 134
  • [6] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] COST-EFFECTIVENESS OF DOSTARLIMAB IN ADVANCED RECURRENT DEFICIENT MISMATCH REPAIR ENDOMETRIAL CANCER PATIENTS
    Dioun, S.
    Chen, L.
    Gockley, A.
    Melamed, A.
    St Clair, C.
    Tergas, A.
    Hou, J.
    Collado, F.
    Wright, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A16 - A16
  • [8] Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
    Ooki, Akira
    Osumi, Hiroki
    Yoshino, Koichiro
    Yamaguchi, Kensei
    GASTRIC CANCER, 2024, 27 (05) : 907 - 931
  • [9] Primary analysis of GEICO 120/DORA, a real-world multicentre study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (DMMR/MSI-H) endometrial cancer
    Gallego, Alejandro
    Madariaga, Ainhoa
    Estevez-Garcia, Purificacion
    Alberti, Facundo
    Carbo, Anna
    Palacio, Isabel
    Churruca, Cristina
    Galvez, Fernando
    Ortega, M. Eugenia
    Murata, Paola
    Manzano, Aranzazu
    Masvidal, Maria
    Martin-Lorente, Cristina
    Hernando, Blanca
    Lozano, Inmaculada
    Cueva, Juan F.
    Garcia-Illescas, David
    Falco, Esther
    Mendiola, Marta
    Redondo, Andres
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A182 - A182
  • [10] Evolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma
    Balmaceda, Nicole Baranda
    Kim, Sunnie S.
    CURRENT ONCOLOGY REPORTS, 2025, 27 (02) : 81 - 94
12345